EHBP1 Antibody

What is EHBP1 and why is it important in cellular research?

EHBP1 (EH domain binding protein 1) functions as an adaptor protein that regulates vesicular trafficking by recruiting Rab8 family members and Eps15-homology domain-containing proteins 1/2 (EHD1/2). It serves as a critical link between endosomes and the actin cytoskeleton, playing essential roles in GLUT4 transport and lipid droplet engulfment during lipophagy in hepatocytes. The protein contains multiple functional domains including an N-terminal C2 domain that associates with PI(3)P, PI(5)P, and phosphatidylserine, a central calponin homology (CH) domain for actin interaction, and a C-terminal bivalent Mical/EHBP Rab binding (bMERB) domain that interacts with Rab8 family members .

How do I select the appropriate EHBP1 antibody for my research?

Selection should be based on:

• Experimental application (WB, IHC, IF, IP, CoIP, ELISA)

• Species reactivity requirements (human, mouse, rat)

• Specific domain targeting needs

• Clonality considerations (polyclonal vs. monoclonal)

Review published validation data and consider antibodies that target specific EHBP1 domains relevant to your research question. For instance, if studying Rab8 interactions, select antibodies targeting the bMERB domain. If investigating membrane associations, choose antibodies recognizing the C2 domain .

What are the typical molecular weights observed for EHBP1 in Western blotting?

EHBP1 typically appears at higher molecular weights than calculated:

This discrepancy between calculated and observed molecular weights is likely due to post-translational modifications or protein conformation characteristics .

What are the recommended dilutions for EHBP1 antibodies across different applications?

Based on multiple vendor recommendations and published protocols:

Always optimize dilutions for your specific experimental system, as sample type and antibody lot can influence optimal conditions .

How can I validate EHBP1 antibody specificity for my experiments?

Implement multiple validation strategies:

• Perform knockdown/knockout validation using EHBP1 RNAi or CRISPR-Cas9 systems

• Use positive control lysates where EHBP1 expression is confirmed (e.g., DU145 cells, HepG2 cells)

• Conduct peptide competition assays with the immunizing peptide

• Compare results with at least one alternative antibody targeting a different epitope

• Include tissue-specific controls that express EHBP1 (e.g., human testis tissue, human lung tissue)

This multi-pronged approach significantly reduces the possibility of non-specific binding artifacts .

What buffer systems are optimal for EHBP1 immunodetection techniques?

For immunohistochemistry, two buffer systems show efficacy:

• Primary: TE buffer pH 9.0 for antigen retrieval

• Alternative: Citrate buffer pH 6.0

For immunoprecipitation and co-immunoprecipitation:

• Lysis buffer containing 50 mM NaCl and protease inhibitors

• For brain tissue: Initial homogenization in Triton X-100-free buffer followed by addition of Triton X-100 (1% v/v final concentration)

These buffer conditions have been experimentally validated in multiple tissue contexts .

How can I investigate EHBP1's interaction with the actin cytoskeleton?

To study the Rab8-dependent activation mechanism of EHBP1's actin-binding activity:

• Perform sequential co-immunoprecipitation studies with both EHBP1 and Rab8 antibodies

• Conduct dual-color immunofluorescence to visualize co-localization with actin structures

• Design experiments comparing wild-type and mutated CH domain constructs

• Investigate the intramolecular CH:bMERB auto-inhibition complex using FRET or proximity ligation assays

• Utilize Rab8 constitutively active (Q67L) and dominant negative (T22N) mutants to modulate EHBP1-actin interactions

This approach allows visualization of how Rab8 binding to the bMERB domain relieves auto-inhibition and enables CH domain interaction with actin .

What methods can be used to study EHBP1's role in vesicular trafficking?

Implement a multi-faceted approach:

• Live-cell imaging with fluorescently tagged EHBP1 constructs to track vesicle dynamics

• Co-localization studies with Rab8/10 and EHD1/2 proteins using multicolor immunofluorescence

• GLUT4 translocation assays in adipocytes with EHBP1 knockdown/overexpression

• Analysis of transferrin uptake and recycling under EHBP1 manipulation conditions

• Structured illumination microscopy to visualize membrane tubulation events

This methodology has successfully elucidated EHBP1's role in coupling endocytic vesicles to the actin cytoskeleton and in GLUT4 transport .

How can I investigate the EHBP1-syndapin interaction in neuronal development?

Based on recent research:

• Perform heterologous co-immunoprecipitation with:

  • Flag-tagged syndapin I, II, and III

  • GFP-tagged EHBP1 proteins

  • Controls using unrelated IgG

• For endogenous co-immunoprecipitation from brain tissue:

  • Prepare brain lysates in Triton X-100-free buffer

  • Incubate with affinity-purified anti-syndapin I antibodies

  • Use protein A/G PLUS agarose for isolation

  • Analyze by immunoblotting with both anti-syndapin I and anti-EHBP1 antibodies

• For functional studies of dendritic arbor formation:

  • Design rescue experiments with RNAi-insensitive EHBP1 constructs

  • Use mutant GFP-EHBP1* sequences to identify critical interaction regions

This approach has revealed EHBP1's critical involvement in dendritic arbor formation .

Why might I observe inconsistent EHBP1 antibody staining patterns across experiments?

Inconsistencies can stem from several factors:

• Antibody validation issues: Johns Hopkins researchers documented that approximately 50% of manuscripts contained potentially incorrect IHC staining results due to inadequate antibody validation practices

• Isoform specificity: Human and rat EHBP1 have multiple isoforms with tissue-specific expression patterns

• Buffer system variations: Antigen retrieval methods significantly impact epitope accessibility

• Sample preparation differences: Fixation protocols alter protein conformation and epitope exposure

• Lot-to-lot antibody variability: Even antibodies from the same manufacturer can show batch differences

To address these issues, implement standardized validation protocols for each new antibody lot and maintain consistent experimental conditions .

How do I interpret EHBP1 Western blot results with multiple bands?

Multiple bands in EHBP1 Western blots may represent:

• Different isoforms: Human EHBP1 has multiple isoforms, including isoform 1 and isoform 2 (which lacks 35 amino acids compared to isoform 1)

• Post-translational modifications: Phosphorylation can cause band shifts

• Proteolytic processing: C-terminal or N-terminal cleavage during sample preparation

• Non-specific binding: Particularly with polyclonal antibodies

Validation approaches:

• Compare observed band patterns with expected molecular weights

• Perform RNAi knockdown to confirm specificity

• Use recombinant EHBP1 fragments (e.g., EHBP1 399-722) as controls

• Test multiple antibodies targeting different regions of EHBP1 .

What are the common pitfalls in co-immunoprecipitation experiments involving EHBP1?

Avoid these common issues:

• Buffer incompatibilities: EHBP1 co-IP from brain tissue requires initial homogenization in Triton X-100-free buffer

• Inadequate controls: Always include non-immune IgG controls from the same species as your primary antibody

• Crossreactivity issues: Especially problematic when studying interactions with related proteins (e.g., syndapin family members)

• Improper antibody amounts: Use 5 μg of antibody for 1-3 mg of total protein lysate

• Protein degradation: Include complete protease inhibitors in all buffers

For syndapin-EHBP1 interaction studies specifically, the differential use of buffer systems (with or without Triton X-100) during various preparation steps has been shown to be critical .

How can EHBP1 antibodies be used to study its role in lipid metabolism disorders?

EHBP1 forms part of a Rab10-EHBP1-EHD2 trimeric complex crucial for lipid droplet engulfment during lipophagy in hepatocytes. For investigation:

• Implement co-localization studies with markers for:

  • Lipid droplets (BODIPY or Oil Red O)

  • Autophagosomes (LC3)

  • Rab10 and EHD2

• Conduct time-course analyses during lipophagy induction:

  • Analyze EHBP1 localization shifts

  • Compare wild-type and fatty liver disease models

  • Assess differential recruitment of Rab10 vs. other Rab family members

• Use proximity ligation assays to detect in situ protein interactions between:

  • EHBP1 and Rab10

  • EHBP1 and EHD2

  • EHBP1 and actin cytoskeleton components

This approach has provided insights into EHBP1's function in hepatic lipid metabolism .

What new methodologies are being developed to improve EHBP1 antibody specificity and reproducibility?

In response to the "reproducibility crisis" highlighted by Johns Hopkins researchers, emerging approaches include:

• Comprehensive validation pipelines:

  • Genetic knockout controls (CRISPR-Cas9)

  • Phospho-specific validation using phosphatase treatments

  • Cross-platform confirmation (mass spectrometry validation)

• Advanced screening technologies:

  • High-throughput epitope mapping

  • Competitive binding assays against known epitopes

  • In silico prediction of cross-reactivity

• Standardized reporting requirements:

  • Detailed methodology documentation

  • Sharing of validation data in repositories

  • Use of certified reference materials

These approaches aim to address the estimated $2 billion per year spent on research antibodies, a significant portion of which produces unreliable results due to inadequate validation .

How can structural insights into EHBP1 domains inform antibody selection strategies?

Recent structural studies of the CH:bMERB auto-inhibited complex and active bMERB:Rab8 complex provide important considerations:

• For studying inactive EHBP1:

  • Select antibodies recognizing epitopes at the CH:bMERB interface

  • These may preferentially detect the auto-inhibited conformation

• For active EHBP1 detection:

  • Choose antibodies targeting regions exposed after Rab8 binding

  • Consider antibodies specific to the active conformation of the CH domain

• For membrane association studies:

  • Target the N-terminal C2 domain involved in lipid binding

  • Assess accessibility of this domain in membrane-bound vs. cytosolic forms

This structure-guided antibody selection can provide deeper insights into the conformational states of EHBP1 during its activation cycle .